Free shipping on all orders over $ 500

AS1517499

Cat. No. M7539

All AbMole products are for research use only, cannot be used for human consumption.

AS1517499 Structure
Size Price Availability Quantity
1mg USD 50  USD50 In stock
5mg USD 92  USD92 In stock
10mg USD 150  USD150 In stock
25mg USD 300  USD300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: AS1517499 inhibit IL-4-induced Th2 differentiation of mouse spleen T cells, but has no influence on Th1 differentiation induced by IL-12. AS1517499 is able to prevent the IL-4-activated STAT6-mediated increase of the clonogenic potential of primary PCa cells. At a dose of 300 nM, AS1517499 decreases the clonogenic potential of primary basal PCa cells.

In vivo: In vivo treatment with AS1517499 ameliorates the antigen-induced bronchial smooth muscle (BSM) hyperresponsiveness by inhibiting the RhoA up-regulation in BSMs and, at least in part, by reducing the IL-13 production in the airways in mice. AS1517499 reduces preventive effects of apoptotic cell instillation on bleomycin-induced lung fibrosis by suppressing PPARγ.

Protocol (for reference only)
Cell Experiment
Cell lines Normal human BSM cells
Preparation method Cells are maintained in SmBM medium supplemented with 5% fetal bovine serum, 0.5 ng/ml human epidermal growth factor (hEGF), 5 mg/ml insulin, 2 ng/ml human fibroblast growth factor-basic (hFGF-b), 50 mg/ml gentamicin, and 50 ng/ml amphotericin B. Cells are maintained at 37℃ in a humidified atmosphere (5% CO2), fed every 48 to 72 hours, and passaged when cells reached 90 to 95% confluence. Then the hBSMCs (passages 7-9) are seeded in 6-well plates and 8-well chamber slides at a density of 3,500 cells/cm2 and, when 80 to 85% confluence is observed, cells are cultured without serum for 24 hours before addition of recombinant human IL-13. AS1517499, or its vehicle (0.3% DMSO) is treated 30 minutes before the addition of IL-13 (100 ng/ml). In some experiments, AS1517499 is treated 0 (co-incubation), 3, or 12 hours after the addition of IL-13. In another series of experiments, a selective Rho-kinase inhibitor Y-27632 or its vehicle (0.3% DMSO) is also applied 15 minutes before the IL-13 application. At the indicated time after the IL-13 treatment, cells are washed with PBS, immediately collected, and disrupted with 1×SDS sample buffer (250 μl/well), and used for Western blot analyses.
Concentrations 100 nM
Incubation time 30 min
Animal Experiment
Animal models A murine model of allergic bronchial asthma (Male BALB/c mice)
Formulation 20% DMSO in saline
Dosages 1 or 10 mg/kg/d
Administration i.p.
Chemical Information
Molecular Weight 397.86
Formula C20H20ClN5O2
CAS Number 919486-40-1
Solubility (25°C) 79 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Kim MJ, et al. Cell Physiol Biochem. A STAT6 Inhibitor AS1517499 Reduces Preventive Effects of Apoptotic Cell Instillation on Bleomycin-Induced Lung Fibrosis by Suppressing PPARγ.

[2] Sun H, et al. Int J Surg. Partial enteral nutrition increases intestinal sIgA levels in mice undergoing parenteral nutrition in a dose-dependent manner.

Related STAT Products
HP590 

HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM).

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3.

HJC0123

HJC0123 is a novel STAT3 inhibitor that suppresses the fibrogenic properties of HSCs. HJC0123 reduced the phosphorylation, nuclear translocation, and transcriptional activity of STAT3. HJC0123 treatment resulted in the inhibition of HSCs proliferation at submicromolar concentrations. It decreased the expression of STAT3-regulated proteins, induced cell cycle arrest, promoted apoptosis and downregulated SOCS3.

ODZ10117

ODZ10117 is a small molecule inhibitor of STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells.

OPB-111077

OPB-111077 is a first-in-class, novel, oral inhibitor of STAT3 and mitochondrial oxidative phosphorylation (OXPHOS) with anticancer activity. OPB-111077 inhibits mitochondrial respiratory chain complex I, which leads to inhibition of energy production and activation of the AMPK-mTOR energy stress sensor pathway.

  Catalog
Abmole Inhibitor Catalog




Keywords: AS1517499 supplier, STAT, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.